Advances in wilms tumor treatment and biology: Progress through international collaboration

Jeffrey S. Dome, Norbert Graf, James I. Geller, Conrad V. Fernandez, Elizabeth A. Mullen, Filippo Spreafico, Marry Van Den Heuvel-Eibrink, Kathy Pritchard-Jones

Research output: Contribution to journalArticle

Abstract

Clinical trials in Wilms tumor (WT) have resulted in overall survival rates of greater than 90%. This achievement is especially remarkable because improvements in disease-specific survival have occurred concurrently with a reduction of therapy for large patient subgroups. However, the outcomes for certain patient subgroups, including those with unfavorable histologic and molecular features, bilateral disease, and recurrent disease, remain well below the benchmark survival rate of 90%. Therapy for WT has been advanced in part by an increasingly complex risk-stratification system based on patient age; tumor stage, histology, and volume; response to chemotherapy; and loss of heterozygosity at chromosomes 1p and 16q. A consequence of this system has been the apportionment of patients into such small subgroups that only collaboration between large international WT study groups will support clinical trials that are sufficiently powered to answer challenging questions that move the field forward. This article gives an overview of the Children's Oncology Group and International Society of Pediatric Oncology approaches to WT and focuses on four subgroups (stage IV, initially inoperable, bilateral, and relapsed WT) for which international collaboration is pressing. In addition, biologic insights resulting from collaborative laboratory research are discussed. A coordinated expansion of international collaboration in both clinical trials and laboratory science will provide real opportunity to improve the treatment and outcomes for children with renal tumors on a global level.

Original languageEnglish
Pages (from-to)2999-3007
Number of pages9
JournalJournal of Clinical Oncology
Volume33
Issue number27
DOIs
Publication statusPublished - Sep 20 2015

Fingerprint

Wilms Tumor
Clinical Trials
Medical Laboratory Science
Survival Rate
Therapeutics
Benchmarking
Loss of Heterozygosity
Neoplasms
Histology
Chromosomes
Pediatrics
Kidney
Drug Therapy
Survival
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dome, J. S., Graf, N., Geller, J. I., Fernandez, C. V., Mullen, E. A., Spreafico, F., ... Pritchard-Jones, K. (2015). Advances in wilms tumor treatment and biology: Progress through international collaboration. Journal of Clinical Oncology, 33(27), 2999-3007. https://doi.org/10.1200/JCO.2015.62.1888

Advances in wilms tumor treatment and biology : Progress through international collaboration. / Dome, Jeffrey S.; Graf, Norbert; Geller, James I.; Fernandez, Conrad V.; Mullen, Elizabeth A.; Spreafico, Filippo; Van Den Heuvel-Eibrink, Marry; Pritchard-Jones, Kathy.

In: Journal of Clinical Oncology, Vol. 33, No. 27, 20.09.2015, p. 2999-3007.

Research output: Contribution to journalArticle

Dome, JS, Graf, N, Geller, JI, Fernandez, CV, Mullen, EA, Spreafico, F, Van Den Heuvel-Eibrink, M & Pritchard-Jones, K 2015, 'Advances in wilms tumor treatment and biology: Progress through international collaboration', Journal of Clinical Oncology, vol. 33, no. 27, pp. 2999-3007. https://doi.org/10.1200/JCO.2015.62.1888
Dome, Jeffrey S. ; Graf, Norbert ; Geller, James I. ; Fernandez, Conrad V. ; Mullen, Elizabeth A. ; Spreafico, Filippo ; Van Den Heuvel-Eibrink, Marry ; Pritchard-Jones, Kathy. / Advances in wilms tumor treatment and biology : Progress through international collaboration. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 27. pp. 2999-3007.
@article{679472a78ffa43f39ecbd7249e5d4ae8,
title = "Advances in wilms tumor treatment and biology: Progress through international collaboration",
abstract = "Clinical trials in Wilms tumor (WT) have resulted in overall survival rates of greater than 90{\%}. This achievement is especially remarkable because improvements in disease-specific survival have occurred concurrently with a reduction of therapy for large patient subgroups. However, the outcomes for certain patient subgroups, including those with unfavorable histologic and molecular features, bilateral disease, and recurrent disease, remain well below the benchmark survival rate of 90{\%}. Therapy for WT has been advanced in part by an increasingly complex risk-stratification system based on patient age; tumor stage, histology, and volume; response to chemotherapy; and loss of heterozygosity at chromosomes 1p and 16q. A consequence of this system has been the apportionment of patients into such small subgroups that only collaboration between large international WT study groups will support clinical trials that are sufficiently powered to answer challenging questions that move the field forward. This article gives an overview of the Children's Oncology Group and International Society of Pediatric Oncology approaches to WT and focuses on four subgroups (stage IV, initially inoperable, bilateral, and relapsed WT) for which international collaboration is pressing. In addition, biologic insights resulting from collaborative laboratory research are discussed. A coordinated expansion of international collaboration in both clinical trials and laboratory science will provide real opportunity to improve the treatment and outcomes for children with renal tumors on a global level.",
author = "Dome, {Jeffrey S.} and Norbert Graf and Geller, {James I.} and Fernandez, {Conrad V.} and Mullen, {Elizabeth A.} and Filippo Spreafico and {Van Den Heuvel-Eibrink}, Marry and Kathy Pritchard-Jones",
year = "2015",
month = "9",
day = "20",
doi = "10.1200/JCO.2015.62.1888",
language = "English",
volume = "33",
pages = "2999--3007",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "27",

}

TY - JOUR

T1 - Advances in wilms tumor treatment and biology

T2 - Progress through international collaboration

AU - Dome, Jeffrey S.

AU - Graf, Norbert

AU - Geller, James I.

AU - Fernandez, Conrad V.

AU - Mullen, Elizabeth A.

AU - Spreafico, Filippo

AU - Van Den Heuvel-Eibrink, Marry

AU - Pritchard-Jones, Kathy

PY - 2015/9/20

Y1 - 2015/9/20

N2 - Clinical trials in Wilms tumor (WT) have resulted in overall survival rates of greater than 90%. This achievement is especially remarkable because improvements in disease-specific survival have occurred concurrently with a reduction of therapy for large patient subgroups. However, the outcomes for certain patient subgroups, including those with unfavorable histologic and molecular features, bilateral disease, and recurrent disease, remain well below the benchmark survival rate of 90%. Therapy for WT has been advanced in part by an increasingly complex risk-stratification system based on patient age; tumor stage, histology, and volume; response to chemotherapy; and loss of heterozygosity at chromosomes 1p and 16q. A consequence of this system has been the apportionment of patients into such small subgroups that only collaboration between large international WT study groups will support clinical trials that are sufficiently powered to answer challenging questions that move the field forward. This article gives an overview of the Children's Oncology Group and International Society of Pediatric Oncology approaches to WT and focuses on four subgroups (stage IV, initially inoperable, bilateral, and relapsed WT) for which international collaboration is pressing. In addition, biologic insights resulting from collaborative laboratory research are discussed. A coordinated expansion of international collaboration in both clinical trials and laboratory science will provide real opportunity to improve the treatment and outcomes for children with renal tumors on a global level.

AB - Clinical trials in Wilms tumor (WT) have resulted in overall survival rates of greater than 90%. This achievement is especially remarkable because improvements in disease-specific survival have occurred concurrently with a reduction of therapy for large patient subgroups. However, the outcomes for certain patient subgroups, including those with unfavorable histologic and molecular features, bilateral disease, and recurrent disease, remain well below the benchmark survival rate of 90%. Therapy for WT has been advanced in part by an increasingly complex risk-stratification system based on patient age; tumor stage, histology, and volume; response to chemotherapy; and loss of heterozygosity at chromosomes 1p and 16q. A consequence of this system has been the apportionment of patients into such small subgroups that only collaboration between large international WT study groups will support clinical trials that are sufficiently powered to answer challenging questions that move the field forward. This article gives an overview of the Children's Oncology Group and International Society of Pediatric Oncology approaches to WT and focuses on four subgroups (stage IV, initially inoperable, bilateral, and relapsed WT) for which international collaboration is pressing. In addition, biologic insights resulting from collaborative laboratory research are discussed. A coordinated expansion of international collaboration in both clinical trials and laboratory science will provide real opportunity to improve the treatment and outcomes for children with renal tumors on a global level.

UR - http://www.scopus.com/inward/record.url?scp=84942245273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942245273&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.62.1888

DO - 10.1200/JCO.2015.62.1888

M3 - Article

C2 - 26304882

AN - SCOPUS:84942245273

VL - 33

SP - 2999

EP - 3007

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 27

ER -